Anji Biotech

News Center

Good News! Anji Biotech Wins Second Place in the 7th China Returnee Entrepreneurship Competition (First Place among Biomedical Projects)

Good News! Anji Biotech Wins Second Place in the 7th China Returnee Entrepreneurship Competition (First Place among Biomedical Projects)

From June 27 to 30, the semifinals and finals of the 7th China Returnee Entrepreneurship Competition, co-hosted by the China Technology Entrepreneurship Association Returnee Start-up Park Alliance and the People's Government of Changping District, Beijing, were successfully held online. Nearly a hundred returnee entrepreneurship projects competed against each other, with 20 projects advancing to the finals. In the end, the "Anti-aging Peptide Drug R&D" project of Nanjing Anji Biotech Co., Ltd.'s technology team ranked second in the overall score and first among biomedical projects.

Prof. Hanmei Xu's Team and Prof. David J. Craik's Team Propose Renaming ncRNA to pcRNA (potential coding RNA)

The discovery of micropeptides is an emerging topic in the ncRNA (non-coding RNA) field. Initially considered non-coding, advances in gene editing and multi-omics have deepened micropeptide research - scientists have gradually found that some ncRNAs do possess coding potential, and some of the micropeptides they encode exhibit tumor-type specificity and can serve as tumor-specific target molecules, potentially acting as new targets or molecular markers for tumor diagnosis, treatment and prognosis in the future.

Good News! Anji Biotech Wins Second Place in the 7th China Returnee Entrepreneurship Competition (First Place among Biomedical Projects)

From June 27 to 30, the semifinals and finals of the 7th China Returnee Entrepreneurship Competition, co-hosted by the China Technology Entrepreneurship Association Returnee Start-up Park Alliance and the People's Government of Changping District, Beijing, were successfully held online. Nearly a hundred returnee entrepreneurship projects competed against each other, with 20 projects advancing to the finals. In the end, the "Anti-aging Peptide Drug R&D" project of Nanjing Anji Biotech Co., Ltd.'s technology team ranked second in the overall score and first among biomedical projects.

Prof. Wenle Xia Joins Anji Biotech as Chief Advisor

On May 19, 2022, Nanjing Anji Biotech Co., Ltd. formally appointed Dr. (Professor) Wenle Xia as Chief Advisor of its Scientific Committee. Dr. Hanmei Xu, the company's founder and Chief Scientist, formally presented the Chief Scientific Advisor appointment certificate to Dr. Xia, and both parties reached a cooperation intention.

Anji Biotech Reappoints Prof. Edouard Nice as Scientific Advisor

On March 25, 2022, Nanjing Anji Biotech Co., Ltd. held a scientific advisor appointment meeting in its conference room. At the meeting, Anji Biotech appointed Professor Edouard Nice as its scientific advisor. Dr. Hanmei Xu, the company's Chairman and Chief Scientist, formally presented the appointment certificate, and both parties reached a cooperation intention.

Anji Biotech Reappoints Prof. Jean Martinez as Scientific Advisor

The discovery of micropeptides is an emerging topic in the ncRNA (non-coding RNA) field. Initially considered non-coding, advances in gene editing and multi-omics have deepened micropeptide research - scientists have gradually found that some ncRNAs do possess coding potential, and some of the micropeptides they encode exhibit tumor-type specificity.

Peptide Drug Development & Innovation Symposium (First Session)

The discovery of micropeptides is an emerging topic in the ncRNA (non-coding RNA) field. Initially considered non-coding, advances in gene editing and multi-omics have deepened micropeptide research - scientists have gradually found that some ncRNAs do possess coding potential, and some of the micropeptides they encode exhibit tumor-type specificity.